Insights into freeze-thaw processes for therapeutic protein formulations

Conference Dates

July 14-17, 2019


For transport logistical reasons and for the decoupling of DS and DP shelf-life, most Biologics Bulk Drug Substances (BDS) are frozen and thawed before further processing. There are contradictory reports and publications on the influence of freezing processes - sometimes ultra-fast freezing is worse in terms of increased aggregate formation, sometimes slow freezing is inferior. Effects may only be visible upon subsequent long time storage (1, 2). The influence of the thawing process is usually neglected in the considerations and investigations, although here also protein can be damaged.

Please click Additional Files below to see the full abstract.

This document is currently not available here.